Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
The updated data from the mupadolimab study will be presented in a poster at SITC. Details of the poster presentation are as follows:
Title: | Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) |
Presenter: | |
Category: | Immune-stimulants and immune modulators |
Poster #: | 701 |
Date & Time: | |
Location: | Walter E. Washington |
Conference Call, Webcast and Presentation Slides
Corvus will host a conference call and webcast on
About Corvus Pharmaceuticals
About Mupadolimab
Mupadolimab (CPI-006) is an investigational, potent humanized monoclonal antibody that is designed to react with a specific site on CD73. In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. While there are other anti-CD73 antibodies and small molecules in development for treatment of cancer, such agents react with a different region of CD73. Mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine. Mupadolimab is being studied in combination with pembrolizumab in a Phase 1b/2 study in patients with advanced head and neck cancers and in patients with NSCLC that have failed chemotherapy and anti-PD(L)1 therapy. It is postulated that the activation of B cells will enhance immunity within the tumors of these patients, leading to improved clinical outcomes.
INVESTOR CONTACT:
Chief Financial Officer
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
Source: Corvus Pharmaceuticals, Inc.